Neurocine’s mid-stage trial drug cuts schizophrenia severity symptoms
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.
Drugs
Health
Pharma